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Abstract
Previous works have documented the contribution of different IL28B-associated SNPs to spontaneous HCV clearance. This
study investigated the effect of different interleukin (IL) 28B genetic variants on interferon (IFN)-based therapy response. We
genotyped eight IL28B single-nucleotide polymorphisms (SNPs) in a cohort of 197 hepatitis C virus (HCV)/human
immunodeficiency virus type 1 (HIV-1) coinfected patients from our clinic unit who received combined pegylated (peg)-IFN-
a and ribavirin (RBV) therapy. This analysis included the two strongest tag predictors for HCV clearance, rs8099917 and
rs12979860, and four causal variants (rs4803219, rs28416813, rs8103142, and rs4803217) located in the IL28B promoter,
coding, and 39-untranslated regions. Haplotypes carrying the major alleles at IL28B SNPs were highly associated with
sustained virological responses (SVRs) after treatment with peg-IFN-a and RBV [odds ratio (OR)=2.5, 95% confidence
interval (CI)=1.6–4.0, 4.0610
25]. Three causal SNP genotypes (rs28416813, rs8103142, and rs4803217) displayed the highest
association with SVRs (OR=3.7, 95% CI=2.0–6.7, p=1.3610
25). All four causal variants were in high linkage disequilibrium,
both among themselves (r
2$0.94) and with the rs12979860 variant (r
2$0.92). In contrast, rs8099917 was in low linkage
disequilibrium with the four causal variants (r
2#0.45) and with the rs12979860 variant (r
2=0.45). These results demonstrate
that rs12979860, compared to rs8099917, may be a better predictor of response to the peg-IFN/RBV treatment among HCV/
HIV-1 coinfected patients. Moreover, causal IL28B variants are strongly associated with treatment SVRs.
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Introduction
The combination of pegylated interferon alpha (peg-IFN-a)
with ribavirin (RBV) has been used to treat hepatitis C virus
(HCV) infection. However, a sustained virological response (SVR;
a negative hepatitis C polymerase chain reaction (PCR) test 6
months after cessation of therapy) for individuals infected with
HCV genotypes 1 or 4 ranges between 40% and 50%. Patients
infected with HCV genotypes 2 or 3 typically achieve SVRs of
nearly 75% after only 6 months of therapy [1,2,3,4]. HCV
genotype has been the most important predictive factor regarding
the treatment response of HCV-infected patients. Nevertheless,
host factors such as age, sex, race, liver fibrosis, and obesity have
also been associated with peg-IFN-a/RBV therapy outcome [5,6].
Four genome-wide association studies have demonstrated that
several highly-correlated, common, single nucleotide polymor-
phisms (SNPs) located near the interleukin 28B gene (IL28B)
strongly predict an SVR to peg-IFN-a/RBV therapy [7,8,9,10].
Il28B polymorphisms have been also strongly associated with SVR
in HCV/HIV-1 coinfected patients [11,12,13,14,15,16]. Two
SNPs in particular (rs12979860 and rs8099917, located 3 and
7.5 kb upstream of the IL28B gene, respectively) were the
strongest predictors for HCV clearance. The recent approval of
direct-acting antiviral (DAA) molecules, the NS3 protease
inhibitors telaprevir and bocebrevir, active on HCV will represent
a major breakthrough for HCV infected patients. Because of the
low genetic resistance of first-generation protease inhibitors most
failures to a triple combination of peg-IFN-a/RBV and either
telaprevir o boceprevir will be due to a poor response to peg-IFN-
a and RBV. Predictors of SVR to former triple combination will
be also included the IL28B genotype. To determine the best SNP
to predict a response to peg-IFN-a/RBV treatment, we studied
the effect of different IL28B genetic variants on IFN-based therapy
response. Not only will this data refine IL28b based predictions of
treatment response, it may also inform studies of IL28b
mechanism in HCV response.
Although the rs12979860 and rs8099917 genotypes have been
independently associated with HCV treatment outcome, whether
these SNPs play a causal role or are merely tagging other unknown
causal variants remains to be elucidated. IL28B (which encodes
IFN-l3) up-regulates interferon-stimulated genes, similar to IFN-a
and IFN-b, but via a different receptor. There is also evidence that
IFN-l 3 affects the adaptive immune response [17,18]. Moreover,
IFN-l molecules inhibit HCV replication in vitro, and trials of
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results that suggest a mechanistic link between IL28B variants and
HCV treatment outcome [19]. Recently, four SNPs located in the
promoter (rs4803219 and rs28416813), coding (rs8103142), and
39-untranslated (rs4803217) regions of IL28B have been shown to
be highly associated with spontaneous HCV clearance [20].
Therefore, we assessed the influence of four causal IL28B variants
(rs4803219, rs28416813, rs8103142, and rs4803217) on SVR to
IFN-based therapies, and compared the relationships of these four
causal SNPs with the tag IL28B variants rs12979860 and
rs8099917.
We previously established the strong relationships between the
rs8099917 G allele and treatment failure in our cohort of HCV/
HIV-1 coinfected patients [21]. In the present study, was
examined the effect of eight different IL28B genetic variants on
IFN-based therapeutic response in these patients.
Results
In a recent study, four causal SNPs (rs4803219, rs28416813,
rs8103142, and rs4803217) were associated with the two tagging
SNPs that were most strongly associated with spontaneous HCV
clearance (rs12979860 and rs8099917) [20]. In this study, the four
causal SNPs and two tagged SNPs were genotyped along with two
additional SNPs, rs11881222 and rs8113007, which are located in
the second IL28B intron and 7.5 kb upstream of the IL28B gene,
respectively (Figure 1). These eight SNPs were genotyped in a
cohort of 197 HCV/HIV-1 coinfected patients from our clinic
unit who received standard combined peg-IFN-a/RBV therapy.
The clinical characteristics and HCV treatment responses of
the197 HCV/HIV-1 coinfected patients included in the study are
summarized in Table 1. Most patients were on antiretroviral
therapy (n=196, 99.5%), and most patients had controlled HIV-1
replication (n=169, 86%). Eighty-three patients (42%) responded
successfully to HCV treatment (i.e., achieved SVR). When the
HIV-1 viral load was compared in the HIV-1 viremic patients
(n=28, 14%), no significant differences were observed between
SVRs and patients failing therapy (p=0.1612, Mann-Whitney U
test). Similarly, the length of time patients were under antiretro-
viral treatment did not impact HCV SVR (p=0.3439, Mann-
Whitney U test). HCV genotype was significantly associated with
SVR in our study cohort (p=7.2610
25) (Table 1). Unexpectedly,
older patients were more likely to achieve HCV SVR (p=0.0223)
(Table 1). Nevertheless, the difference between the means was very
limited (48.5 vs 47 years). A moderate association with SVR was
also observed with patient AST liver enzyme level (p=0.0353),
and HCV viral load (p=0.0120). These four clinical parameters
are known to be associated with HCV treatment response.
All major IL28B single-allele SNPs were highly associated with
SVRs (Table 2). Three causal major alleles, rs28416813,
rs8103142, and rs4803217, demonstrated the highest individual
associations with SVRs (OR=2.9, 95% CI=1.8–4.6,
p=6.6610
26) (Table 2). As shown in Table 3, genotype
distributions of all tested IL28B SNPs were significantly different
among patients experiencing an SVR to peg-IFN-a/RBV
treatment. Again, the causal SNPs rs28416813, rs8103142, and
rs4803217 demonstrated the highest associations with SVRs
(OR=3.7, 95% CI=2.0–6.7, p=1.3610
25) (Table 3). The four
causal variants were in high linkage disequilibrium among
themselves (r
2$0.94) and with the tag rs12979860 variant
(r
2$0.92) (Figure 2). Importantly, rs8099917 was in low linkage
disequilibrium with the four causal variants (r
2#0.45) and with the
rs12979860 variant (r
2=0.45), demonstrating that this SNP was
only moderately linked to the causal SNPs in the IL28B gene.
Notably, the tag rs8113007 variant (which is separated from the
rs8099917 SNP by only 72 nucleotides) displayed intermediate
linkage with the tag rs12979860 (r
2=0.78) and the causal IL28B
gene SNPs (r
2=0.77–0.82). The rs11881222 SNP, located in the
second IL28B intron (Figure 1), was highly linked to both the
causal IL28B SNPs (r
2$0.92) and the tag rs12979860 variant
(r
2=0.92) (Figure 2).
Haplotypes carrying major alleles at IL28B were most strongly
associated with an SVR to peg-IFN-a/RBV therapy (OR=2.5,
95% CI=1.6–4.0, p=4.0610
25) (Table 4). These major
haplotypes were visibly augmented in patients experiencing an
SVR (Tables 2 and 4). Nevertheless, the prognostic value of the
eight haplotypes together was not higher than the ORs obtained
when the different haplotypes were analyzed individually (Table 2).
Importantly, homozygosity for the three of the four causal IL28B
gene SNPs, rs28416813, rs8103142, and rs4803217, was com-
pletely linked to the rs12979860 major CC genotype (r
2=1.0). In
contrast, the rs8099917 major TT genotype demonstrated a lower




Prior work has documented the contribution of different IL28B-
associated SNPs to spontaneous HCV clearance [7,8,9,10,22].
Specifically, di Iulio et al. report the strong association of four
Figure 1. IL28B gene locus and position of single nucleotide polymorphisms (SNPs) analyzed in this study.
doi:10.1371/journal.pone.0031016.g001
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of IL28B with spontaneous HCV clearance [20]. However, this
study did not focus on patients treated with IFN-based therapies.
In the present study, we tested the influence of four causal IL28B
variants (rs4803219, rs28416813, rs8103142, and rs4803217) on
SVR to peg-IFN-a/RBV therapy, and compared the relationships
of these four causal SNPs with the tag IL28B variants rs12979860
and rs8099917.
In the present cohort of HCV/HIV-1 coinfected patients, three
major causal IL28B variant haplotypes (rs28416813, rs8103142,
and rs4803217, located in the promoter, coding, and 39-
untranslated regions of IL28B) were highly associated with SVR
to peg-IFN-a/RBV therapy. Moreover, these three haplotypes,
which were in perfect linkage equilibrium among themselves
(r
2=1.0), had a higher odds ratio regarding HCV clearance than
the three tag IL28B SNPs tested here (rs8099917, rs8113007, and
rs12979860). Two of these tag SNPs, rs8099917 and rs12979860,
demonstrated the strongest associations with HCV clearance in
the above-mentioned genome-wide association studies and are
currently being introduced in clinical algorithms to predict SVR to
IFN-based therapies. Another important finding of our study is the
strong linkage of the tag rs12979860 variant with the IL28B causal
SNPs. Homozygosity for the tag rs12979860 variant completely
tagged (r
2=1.0) homozygosity for three major causal SNPs:
rs28416813, rs8103142, and rs4803217. This result suggests that
rs12979860 may be a better marker for IL28B phenotype than
rs8099917 or rs8113007. These findings extend those of di Iulio et
al., confirming that rs12979860 can be a better predictor for HCV
clearance, as well as underscoring the strong association of causal
IL28B SNPs with HCV clearance [20]. Most notably, to our
knowledge this is the first study to investigate the association of
IL28B tag and causal variants with patient response to peg-IFN-a/
RBV therapy. These results provide compelling evidence for the
relationship between IL28B tag and causal variants, and suggest
possible involvement of the IL28B gene product, IFN-l3, in SVR
to IFN-based therapies. However, some limitations are worth
noting. First, our study was restricted to an ethnically and
epidemiologically homogeneous cohort of HCV/HIV-1 coinfect-
ed patients attending our clinic. Future work should include other
ethnic and patient cohorts. Second, as previously suggested [20],
functional studies are needed to precisely identify the host gene
variants implicated in the control of HCV infection. Two studies
found higher levels of IFN-l2 and IFN-l3 messenger RNAs in
PBMCs from healthy individuals carrying the homozygous
rs8099917 genotype associated with HCV clearance [8,9].
However, another study observed no association between hepatic
expression of IFN-l2 and IFN-l3 and rs8099917 genotype [23].
In short, the data shown here strongly support the association of
tag and causal IL28B variants with HCV clearance after IFN-
based therapy. Nevertheless, there were patients carrying alleles
associated with clearance who did not clear the virus, as well as
patients that carrying alleles not associated with clearance who
were able to clear the virus. These results suggest that further
studies should be conducted to investigate IL28B genetics, as well
as other genetic factors associated with HCV clearance.
Materials and Methods
Patients
One hundred ninety-seven Caucasian HCV/HIV-1 coinfected
patients from our HIV clinic unit who had a standard course of
treatment with peg-IFN-a plus RBV with known virological
response at 24 weeks post-treatment were included in this study.
Treatment success (i.e., achieved SVR) was defined as undetect-
able plasma HCV RNA using a sensitive reverse transcriptase
PCR assay 24 weeks after treatment cessation. HCV genotype,
HCV viral load, HIV-1 viral load, CD4+ T cell count and liver
enzyme levels.
Written informed consent was obtained from each patient who
participated in the study. Similarly, ethical approval was obtained
from our Institutional Review Board (Hospital Universitari
Germans Trias i Pujol).
Table 1. Clinical characteristics of patients with chronic HIV-1
and HCV coinfection who were treated with peg-IFN-a/RBV
therapy.
SVR NSVR p-value
Patients, n (%) 83 (42%) 114 (58%) -
Age (mean 6 SEM) 48.5760.5582 46.9660.5523 0.0223
Sex, n (%) 1.0000
Female 27(44%) 36 (56%)




HCV genotype, n (%) 7.2610
25
1 35 (33%) 70 (67%)
3 41 (66%) 21 (34%)
4 11 (32%) 23 (68%)
Other/Unknown 0 2
ALT (U/l) (mean 6 SEM) 87.7868.22 95.1967.30 ns
AST (U/l) (mean 6 SEM) 59.3164.95 67.8864.04 0.0353






43 (49%) 83 (71%) 0.0047
Undetectable HIV-1 RNA,
n( % )
68 (78%) 93 (80%) ns
ALT: alanine aminotransferase; AST: aspartate aminotransferase; HCV: hepatitis
C virus; HIV-1: human immunodeficiency virus type 1; NSVR: non-sustained
virological response; SVR: sustained virological response.
Age, Mann-Whitney U test; Sex, Chi-squared test; CD4+T cell count, Mann-
Whitney U test; HCV genotype Chi-squared test; ALT and AST, Mann-Whitney U
test; HCV RNA, unpaired t-test; Undetectable HIV-1, Chi-squared test.
doi:10.1371/journal.pone.0031016.t001
Table 2. Association of individual IL28B haplotypes with
sustained virological response to peg-IFN-a/RBV therapy.
SNP Associated Allele OR (95% CI) p-value
rs4803217 C 2.9 (1.8–4.6) 6.7610
26
rs11881222 A 2.8 (1.7–4.5) 1.6610
25
rs8103142 T 2.9 (1.8–4.6) 6.7610
26
rs28416813 C 2.9 (1.8–4.6) 6.7610
26
rs4803219 C 2.8 (1.7–4.5) 1.6610
25
rs12979860 C 2.8 (1.8–4.6) 9.9610
26
rs8113007 A 2.3 (1.4–3.6) 4.0610
24
rs8099917 T 2.7 (1.6–4.6) 2.0610
24
doi:10.1371/journal.pone.0031016.t002
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GenomicDNAwasextractedfromperipheralbloodmononuclear
cells (PBMCs) using the QuickExtract DNA Extraction Protocol
(EPICENTRE Biotechnologies) as previously described [21].
Genotyping of SNPs
SNP genotyping was performed by PCR amplification and
direct PCR sequencing. The rs8099917 and rs8113007 variants
were PCR amplified and sequenced with oligonucleotides
rs8099917–128 (59-GTGCATATGTTTTCTGAC-39, sense) and
rs8099917–556 (59-GAGGCCCCTCACCCATGC-39, antisense).
The PCR amplification mixture contained 5 ml of PBMC
genomic DNA solution, 10 pmol of each oligonucleotide,
200 mM deoxyribonucleoside triphosphates (dNTPs), 2 mM
MgSO4, 16 high-fidelity PCR buffer (Invitrogen), and 0.25 U
Platinum Taq DNA polymerase (Invitrogen) in a total reaction
volume of 50 ml. Cycling parameters were one cycle of
denaturation at 94uC for 2 min; and 40 cycles of denaturation
at 95uC for 30 s, annealing at 55uC for 30 s, and extension at
68uC for 30 s. Extension was followed by a 7-min incubation at
68uC. The resulting 430-nucleotide PCR product was sequenced
using two flanking PCR oligonucleotides (rs8099917–128 and
rs8099917–556) in conjunction with the Big Dye v3.1 kit and the
3100 DNA sequencing system (Applied Biosystems) as described
previously [21]. Sequence alignment and editing were performed
using the Sequencer version 4.1 (GeneCodes) software program.
The rs12979860 SNP was amplified and sequenced with
oligonucleotides rs12979860–13 (59-GACGAGAGGGCGTTA-
GAGC-39, sense) and rs12979860–595 (59-GAGGGACCGC-
TACGTAAGTC-39, antisense). PCR and sequence conditions
were identical to those described above. To genotype the
rs4803219, rs28416813, rs8103142, rs11881222, and rs4803217
variants, a 3308-nucleotide genomic fragment was amplified with
oligonucleotides IL-28-3308F (59-GAGCAGGTGGAATCC-
TCTTG-39, sense) and IL-28-3308R (59-AGCAGGCACCTT-
GAAATGTC-39, antisense). PCR conditions were as described
above, but with PCR extension for 3 min at 68uC. Sequencing
oligonucleotides for this fragment were IL-28-3308F, IL-28-
3308R, rs8103142RV (59-CCATCCTCCCAGCAGTTAACC-
TCCC-39, sense), 2SNPRV (59-TCCCTCCAGCTGCTCAT-
CTGGC-39, sense), and rs4803217RV (59-CCCAGACAG-
CCCCTGACCCA-39, sense).
Statistical analysis
The Mann-Whitney U test, unpaired t-test, and Chi-squared
tests were used to analyze treatment baseline covariates. Chi-
squared tests and contingency tables were used to asses host
genetic associations and to calculate the p-values, odds ratios, and
95% confidence intervals. The above Statistical analyses were
performed using GraphPad Prism version 4.00 for Windows (San
Diego, CA, USA). Linkage disequilibrium and haplotype analyses
were performed using Haploview 4.2 [24].
Table 3. Association of IL28B genotype with sustained virological response to peg-IFN-a/RBV therapy.
Allele SVR NSVR MAF
SNP (1/2) 1/1 1/2 2/2 1/1 1/2 2/2 SVR NSVR OR (95% CI) p-value
rs4803217 C/A 56 23 4 41 55 18 0.19 0.40 3.7 (2.0–6.7) 1.3610
25
rs11881222 A/G 57 22 4 44 53 17 0.18 0.38 3.5 (1.9–6.3) 3.0610
25
rs8103142 T/C 56 23 4 41 55 18 0.19 0.40 3.7 (2.0–6.7) 1.3610
25
rs28416813 C/G 56 23 4 41 55 18 0.19 0.40 3.7 (2.0–6.7) 1.3610
25
rs4803219 C/T 57 22 4 44 53 17 0.18 0.38 3.5 (1.9–6.3) 3.0610
25
rs12979860 C/T 56 23 4 42 54 18 0.19 0.39 3.6 (2.0–6.5) 2.2610
25
rs8113007 A/T 55 20 8 43 54 17 0.22 0.39 3.2 (1.8–5.9) 7.5610
25
rs8099917 T/G 66 13 4 60 44 10 0.13 0.28 3.5 (1.8–6.8) 1.0610
24
MAF: minor allele frequency; NSVR: non-sustained virological response; SVR: sustained virological response. Numbers reflect the number of patients with indicated
genotype.
doi:10.1371/journal.pone.0031016.t003
Figure 2. Pairwise linkage disequilibrium (LD) plot for the eight
single nucleotide polymorphisms (SNPs) analyzed in this
study. The linkage disequilibrium between the four candidate casual
SNPs (rs4803217, rs8103142, rs28416813 and rs4803219) and the
tagging SNPs is shown. An empty square represents r
2=1.0.
doi:10.1371/journal.pone.0031016.g002
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